This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.
TNBC is a particularly aggressive type of cancer, and high expression of Trop-2 in particular is associated with poor survival and relapse. ... The ADC was approved by the US Food and Drug Administration (FDA) in April last year for the treatment of
breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small cell lung cancer (NSCLC).
Merck’s drug suffered a rare set back last year when it failed to show benefits compared to standard chemotherapy in advanced TNBC. ... Despite the fail in TNBC, Keytruda is far ahead of its rivals in terms of revenues, bringing in $11bn last year alone
TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide, approximately 300, 000 cases every year. ... Meanwhile, Merck is also carrying out two additional studies of Keytruda to try to
cancer (NSCLC) and triple-negative breast cancer (TNBC).
Merck also pointed to the potential for Keytruda growth in new indications like renal cell carcinoma, adjuvant melanoma, small-cell lung cancer (SCLC) and triple-negative breast cancer (TNBC), as well
More from news
Approximately 4 fully matching, plus 25 partially matching documents found.
Trop2 is a transmembrane glycoprotein overexpressed in many epithelial cancer cells, including TNBC.
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...